Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILO study: low-dose oral immunotherapy with omalizumab in children with severe cow's milk allergy
2023-503958-12-00Phase 2Authorised
- Sponsor
- Hospital Universitario Niño Jesús
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of omalizumab in Immunoglobulin E-mediated cow's milk allergy, sponsored by Hospital Universitario Niño Jesús. Primary endpoint: Tolerance of 300 mg cow's milk protein without omalizumab. Planned start Sep 2023; status: authorised.
02
Drugs
omalizumab
03
Conditions
Immunoglobulin E-mediated cow's milk allergy
Beyond the preview
Go deeper on 2023-503958-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503958-12-00.